Escitalopram Oxalate
Product Images NDC 10544-230

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Escitalopram Oxalate (NDC 10544-230). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Blenheim Pharmacal, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure-escitalopram Sulfate (Chemical Structure Escitalopram Sulfate)

Chemical structure of escitalopram oxalate, showing its molecular formula including an aromatic ring system with a fluorine substituent, a cyano group, and an oxalate moiety (C2H2O4).*

FDA Label Image

Label Graphic-escitalopram 10 mg 30 Tablets (Label Graphic Escitalopram 10 mg 30 Tablets)

Label for Escitalopram Tablets, USP 10 mg, containing 30 tablets. The label includes dosage form, strength, storage instructions, manufacturer Blenheim Pharmacal, Inc., and identifies the product as prescription only. NDC 10544-225-30 is visible along with manufacturing details and a barcode.*

FDA Label Image

Label Graphic-escitalopram 15 mg 30 Tablets (Label Graphic Escitalopram 15 mg 30 Tablets)

Label for Escitalopram Tablets USP 20 mg, containing 30 tablets, manufactured by Blenheim Pharmacal, Inc. The label includes NDC number 10544-230-30, storage instructions to keep at controlled room temperature 20-25°C, and a barcode. It also states Rx only and advises to see package insert for dosage information.*

FDA Label Image

Label Graphic-escitalopram 5 mg 30 Tablets (Label Graphic Escitalopram 5 mg 30 Tablets)

Label for Escitalopram Tablets, USP 5mg, containing 30 tablets, labeled as Rx Only. The product is manufactured by Blenheim Pharmacal, Inc. Dosage instructions and storage conditions are included, along with an NDC number 10544-224-30. The label displays a barcode and batch information placeholders.*

FDA Label Image

1 (Image 01)

Table listing treatment-emergent adverse reactions occurring with a frequency of 2% or more and greater than placebo in patients with Major Depressive Disorder. It compares the percentage of patients experiencing various adverse reactions under Escitalopram Oxalate (N=715) and placebo (N=592) across categories such as Autonomic Nervous System Disorders, Central & Peripheral Nervous System Disorders, Gastrointestinal Disorders, General, Psychiatric Disorders, Respiratory System Disorders, and Urogenital effects.*

FDA Label Image

2 (Textescitalopram Figure 02)

A data table titled 'TABLE 3' showing treatment-emergent adverse reactions observed with a frequency greater than 2% and higher than placebo for Generalized Anxiety Disorder. The table compares adverse reactions and their percentages between Escitalopram Oxalate (N=429) and placebo (N=427) for various categories including autonomic nervous system disorders, central & peripheral nervous system disorders, gastrointestinal disorders, general symptoms, musculoskeletal system disorders, psychiatric disorders, respiratory system disorders, and urogenital reactions.*

FDA Label Image

Logo (Textescitalopram Figure 04)

FDA Label Image

1 (Textescitalopram Figure 05)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.